Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019
A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carrie...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | español |
| OAI Identifier: | oai:ddd.uab.cat:222686 |
| Acceso en línea: | https://ddd.uab.cat/record/222686 https://dx.doi.org/urn:doi:10.1016/j.arteri.2019.04.002 |
| Access Level: | acceso abierto |
| Palabra clave: | Inhibidores de la proproteína convertasa subtilisina kexina 9 Colesterol Lipoproteínas de baja densidad Tratamiento Indicaciones clínicas Hipercolesterolemia familiar Enfermedad cardiovascular Documento de consenso Número necesario a tratar Proprotein convertase subtilisin kexin 9 inhibitors Low density lipoprotein Treatment Clinical indications Familial hypercholesterolemia Cardiovascular disease Consensus document Number needed to treat |
| Sumario: | A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carried out on a large scale with PCSK9i have shown that in addition to their high potency to lower atherogenic cholesterol, they reduce the risk of atherosclerotic cardiovascular disease, both in patients with stable disease, and with recent disease, and with a high degree of security. This update provides the recommendations and level of evidence for the prescription of iPCSK9 in patients with homozygous and heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease, and in primary prevention in patients with very high cardiovascular risk. These recommendations have been established taking into account the concentration of LDL-C, the clinical situation of the patient, the additional risk factors and the cost-effectiveness of their use. |
|---|